The AZEK Company(AZEK) - 2025 Q2 - Earnings Call Presentation
2025-05-06 20:21
Financial Performance - Q2 2025 net sales increased by 8.1% year-over-year[46] - Adjusted EBITDA Margin increased by 40 bps year-over-year to 27.5%[44, 46] - The company reaffirms FY 2025 net sales outlook between $1.52 billion and $1.55 billion, representing 5% to 8% year-over-year growth[44] - The company reaffirms Adjusted EBITDA outlook between $403 million and $418 million, representing 6% to 10% year-over-year growth[44] - Residential segment growth was at 9% year-over-year[44] Strategic Initiatives and Market Position - The company is the industry leader in outdoor living[17, 36] - The company is benefiting from long-term material conversion trends[16] - The company is targeting double-digit annual net sales growth[17] - The company is expanding Adj EBITDA margin to a target of approximately 27.5%[17] - The company estimates that wood alternative decking could reach approximately 50% of decking opportunities share over the next 10-15 years and up to 75% over time[33]
Revolve(RVLV) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:21
Financial Performance - Net sales increased by 10% year-over-year, from $270.6 million in Q1 2024 to $296.7 million in Q1 2025[11] - Adjusted EBITDA increased by 45% year-over-year, from $13.3 million in Q1 2024 to $19.3 million in Q1 2025[11] - Adjusted EBITDA margin increased by 160 basis points year-over-year, reaching 6.5% in Q1 2025[11] - Net income increased by 5% year-over-year, from $10.9 million in Q1 2024 to $11.4 million in Q1 2025, Q1 2024 included an insurance recovery equivalent to $2.1 million, net of tax[11] - Diluted EPS (GAAP) increased by 7% year-over-year, from $0.15 in Q1 2024 to $0.16 in Q1 2025, Q1 2024 EPS included an insurance recovery equivalent to $0.03 per share[25] Segment and Geographic Performance - REVOLVE net sales increased by 11% year-over-year, from $229.6 million in Q1 2024 to $254.4 million in Q1 2025[13] - FWRD net sales increased by 3% year-over-year, from $41.0 million in Q1 2024 to $42.3 million in Q1 2025[13] - U S net sales increased by 9% year-over-year, from $219.1 million in Q1 2024 to $239.2 million in Q1 2025[13] - International net sales increased by 12% year-over-year, from $51.4 million in Q1 2024 to $57.5 million in Q1 2025[13] Cash Flow and Balance Sheet - Free cash flow increased by 17% year-over-year, from $36.7 million in Q1 2024 to $42.8 million in Q1 2025[30] - Cash and cash equivalents increased by $44 million, or 17% quarter-over-quarter, reaching $300.8 million in Q1 2025[30]
Arcutis Biotherapeutics(ARQT) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:20
1 st Quarter 2025 Financial Results & Business Update May 6, 2025 Legal Disclaimers This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financia ...
Standard BioTools(LAB) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:20
Setting Standards Empowering Research Building Shareholder Value First Quarter 2025 Financial Results May 6th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words "believes," "plans," "anticip ...
Tempus Ai,Inc.(TEM) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:20
Tempus AI, Inc. Investor Presentation Q1 2025 May 6, 2025 Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.'s (the "Company" or "Tempus") current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include all statements that are not historical facts. Such forward-looking statements are subject to various risks and uncertaint ...
Dynavax(DVAX) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:18
Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases Advance Differentiated Vaccine Pipeline Identify Strategic Opportunities to Accelerate Growth © Copyright DYNAVAX 2025 3 | May 2025 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statement ...
Arcus Biosciences(RCUS) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:18
COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. May 6, 2025 CORPORATE PRESENTATION Notice of Trademark: The Arcus name and logo are the property of Arcus. All other trademarks used herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of Arcus. Forward-Looking Statements/Safe Harbor Forward Looking Statements ...
Klaviyo(KVYO) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:17
Q1 2025 Investor Presentation 05.06.2025 This presentation includes certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Other than statements of historical facts, all statements contained in this presentation and accompanying oral commentary, including, but not limited to, statements about Klaviyo's outlook for the second quarter of fiscal year 2025 and the full fiscal year ending December 31, 2025, and Kl ...
Halozyme(HALO) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:17
Financial Performance - Q1 2025 - Total revenue reached $265 million, a 35% increase compared to the same period last year[9] - Royalty revenue increased by 39% to $168 million[9] - GAAP net income was $118 million, a 54% increase[9] - GAAP diluted EPS increased by 55% to $0.93, while non-GAAP diluted EPS increased by 41% to $1.11[9] - Adjusted EBITDA increased by 40% to $162 million[9] Key Products & Growth Drivers - DARZALEX® SC U S market share is approximately 95%[11] - DARZALEX® sales reached $3.2 billion in Q1 2025, a 22% year-over-year increase[12] - Phesgo® sales are projected to reach $3.3 billion in 2028[14], with Q1 2025 revenue at approximately $675 million, a 52% year-over-year increase[15] - VYVGART® & VYVGART® Hytrulo SC are projected for blockbuster growth to approximately $7 billion in 2028[18] Financial Outlook & Capital Allocation - The company announced a new $250 million share repurchase program[10, 37] - The company projects approximately $1 billion of royalty revenue in 2027[31] - Total revenue for 2025 is guided between $1200 million and $1280 million[40]
loanDepot(LDI) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:16
Revenue +6% QoQ +23% $274M YoY Q1 2025 -7% QoQ +11% YoY Origination vol. market share (1) 1.3% Market share PTNI -$46M Q1 2025 +45% QoQ +46% YoY PTNI +7% QoQ +29% 1.9% YoY Unit share Volume share Conv / Gov Delta: -5 / +1% QoQ -15 / +5% YoY Product Mix 1Q '25 FINANCIAL HIGHLIGHTS UPB & servicing revenue +1% QoQ -18% YoY UPB Expenses by Category $223 $265 $315 $257 $274 $0 $100 $200 $300 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Revenue ($M) $142 $114 $115 $116 $117 $70 $100 $130 $100 $140 Q1 '24 Q2 '24 Q3 '24 Q4 ' ...